metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
versus placebo
	pembrolizumab alone vs. placebo	1		-
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-		-
	atezolizumab plus bevacizumab vs. sunitinib	2			-
	avelumab plus axitinib vs. sunitinib	1			-
	nivolumab plus cabozantinib vs. sunitinib	1			-
	nivolumab plus ipilimumab vs. sunitinib	3			-
	pembrolizumab plus axitinib vs. sunitinib	1			-
	pembrolizumab plus lenvatinib vs. sunitinib	1			-
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative
versus sunitinib
	atezolizumab plus bevacizumab vs. sunitinib	1	-		-
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-		-
	atezolizumab plus bevacizumab vs. sunitinib	2			-
	avelumab plus axitinib vs. sunitinib	1			-
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone vs. everolimus	1			-